UP FRONT
American Society of Clinical
Oncology Annual Meeting
June 3 – 8, 2016
Chicago, IL
ASCO brings together 30,000 oncology professionals
from around the world, with educational sessions on
new therapies and the latest ground-breaking research.
European Hematology Association
Annual Congress
June 9 – 12, 2016
Copenhagen, Denmark
The 21st Annual Congress will provide a forum for sharing clinical and translational research in hematologic
disorders and disseminating evidence-based knowledge.
ASH Meeting on Lymphoma Biology
June 18 – 21, 2016
Colorado Springs, CO
The ASH Meeting on Lymphoma Biology brings together
experts from around the world to discuss the latest
breakthroughs in basic and translational lymphoma
research, address current challenges in the field, and
exchange ideas on how to move the field forward.
ASH Workshop on Genome Editing
July 14 – 15, 2016
Washington, DC
The ASH Workshop on Genome Editing provides a forum
that focuses specifically on the mechanistic aspects and
possible clinical applications of this technology to blood
disorders, as well as a platform for the exchange of ideas
between academic researchers, industry scientists, and
regulators involved in the clinical application of genome
editing technology.
International Society of Experimental
Hematology 45th Annual Scientific Meeting
The kidney is a route of excretion for monomethyl auristatin E (MMAE). The pharmacokinetics and safety of
The
The
kidney
kidneyisisaaroute
routeofofexcretion
excretionfor
formonomethyl
monomethylauristatin
auristatinEE(MMAE).
(MMAE).The
Thepharmacokinetics
pharmacokineticsand
andsafety
safetyofof
vedotin and
and MMAE
MMAE were
were evaluated
evaluated after
after the
the administration
administration of 1.2
1.2 mg/kg
mg/kg of ADCETRIS
ADCETRIS to
to patients
patients
brentuximab
vedotin
brentuximab
brentuximabvedotin
and MMAE
were evaluated
after the
administration ofof1.2
mg/kg ofofADCETRIS
to patients
with
mild (CLcr
(CLcr >50-80
>50-80 mL/min;
mL/min; n=4),
n=4), moderate
moderate (CLcr
(CLcr 30-50
30-50 mL/min;
mL/min; n=3)
n=3) and
and severe
severe (CLcr
(CLcr <30
<30 mL/min;
mL/min;
withmild
mild
with
(CLcr >50-80
mL/min; n=4),
moderate (CLcr
30-50 mL/min;
n=3) and
severe (CLcr
<30 mL/min;
n=3)
renal
impairment.
In
patients
with
severe
renal
impairment,
the
rate
of
Grade
3
or
worse
adverse
n=3)renal
renalimpairment.
impairment.InInpatients
patientswith
withsevere
severerenal
renalimpairment,
impairment,the
therate
rateofofGrade
Grade33or
orworse
worseadverse
adverse
n=3)
reactions
was
3/3
(100%)
compared
3/8
(38%)
patients
with
normal
renal
function.
Additionally,
the
reactionswas
was3/3
3/3(100%)
(100%)compared
comparedtoto
to3/8
3/8(38%)
(38%)inin
inpatients
patientswith
withnormal
normalrenal
renalfunction.
function.Additionally,
Additionally,the
the
reactions
AUC
MMAE
(component
ADCETRIS)
was
approximately
2-fold
higher
patients
with
severe
renal
AUCofof
ofMMAE
MMAE(component
(componentofof
ofADCETRIS)
ADCETRIS)was
wasapproximately
approximately2-fold
2-foldhigher
higherinin
inpatients
patientswith
withsevere
severerenal
renal
AUC
impairment
compared
to
patients
with
normal
renal
function.
Due
to
higher
MMAE
exposure,
≥Grade
3
impairment
compared
to
patients
with
normal
renal
function.
Due
to
higher
MMAE
exposure,
≥Grade
3
impairment compared to patients with normal renal function. Due to higher MMAE exposure, ≥Grade 3
adverse
reactions
may
be
more
frequent
patients
with
severe
renal
impairment
compared
patients
with
adversereactions
reactionsmay
maybe
bemore
morefrequent
frequentinin
inpatients
patientswith
withsevere
severerenal
renalimpairment
impairmentcompared
comparedtoto
topatients
patientswith
with
adverse
normal
renal
function.
normalrenal
renalfunction.
function.
normal
Hepatic
Impairment
HepaticImpairment
Impairment
Hepatic
Avoid
the
use
ADCETRIS
patients
with
moderate
severe
hepatic
impairment.
Avoidthe
theuse
useofof
ofADCETRIS
ADCETRISinin
inpatients
patientswith
withmoderate
moderateoror
orsevere
severehepatic
hepaticimpairment.
impairment.
Avoid
The
liver
route
clearance
for
MMAE.
The
pharmacokinetics
and
safety
brentuximab
vedotin
and
Theliver
liverisis
isaaaroute
routeofof
ofclearance
clearancefor
forMMAE.
MMAE.The
Thepharmacokinetics
pharmacokineticsand
andsafety
safetyofof
ofbrentuximab
brentuximabvedotin
vedotinand
and
The
MMAE
were
evaluated
afterthe
theadministration
administrationofof
of1.2
1.2mg/kg
mg/kgofof
ofADCETRIS
ADCETRIStoto
topatients
patientswith
withmild
mild(Child-Pugh
(Child-PughA;A;
A;
MMAEwere
wereevaluated
evaluatedafter
after
the
administration
1.2
mg/kg
ADCETRIS
patients
with
mild
(Child-Pugh
MMAE
n=1),
moderate
(Child-Pugh
B;
n=5)
and
severe
(Child-Pugh
C;
n=1)
hepatic
impairment.
In
patients
with
n=1),moderate
moderate(Child-Pugh
(Child-PughB;B;n=5)
n=5)and
andsevere
severe(Child-Pugh
(Child-PughC;C;n=1)
n=1)hepatic
hepaticimpairment.
impairment.InInpatients
patientswith
with
n=1),
moderate
or
severe
hepatic
impairment,
the
rate
of
≥Grade
3
adverse
reactions
was
6/6
(100%)
compared
moderateororsevere
severehepatic
hepaticimpairment,
impairment,the
therate
rateofof≥Grade
moderate
≥Grade33adverse
adversereactions
reactionswas
was6/6
6/6(100%)
(100%)compared
compared
3/8
(38%)
patients
with
normal
hepatic
function.
Additionally,
the
AUC
MMAE
was
approximately
to3/8
3/8(38%)
(38%)inin
inpatients
patientswith
withnormal
normalhepatic
hepaticfunction.
function.Additionally,
Additionally,the
theAUC
AUCofof
ofMMAE
MMAEwas
wasapproximately
approximately
toto
2.2-fo